0
     

Report Added
Report already added
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drugs In Development, 2022, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline landscape.

Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female, hereditary disease that affects the adrenal glands, age and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in chest and abdomen, early signs of puberty in children, increased facial and body hair, particularly in females and deepened voice in females.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 11, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Corcept Therapeutics Inc
Eisai Co Ltd
Enterome Bioscience SA
Exelixis Inc
Fusion Pharmaceuticals Inc
GSK plc
Infinity Pharmaceuticals Inc
Merck & Co Inc
Merck KGaA
Orphagen Pharmaceuticals Inc
Pharma Mar SA
Sanofi
Seneca Therapeutics Inc
Tempest Therapeutics Inc
Y-mAbs Therapeutics Inc
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drug Profiles
8H-9 - Drug Profile
Product Description
Mechanism Of Action
avelumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
cabazitaxel - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cabometyx - Drug Profile
Product Description
Mechanism Of Action
History of Events
derazantinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
dostarlimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
ecubectedin - Drug Profile
Product Description
Mechanism Of Action
History of Events
eganelisib - Drug Profile
Product Description
Mechanism Of Action
History of Events
EO-2401 - Drug Profile
Product Description
Mechanism Of Action
History of Events
FPI-1434 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ipilimumab + nivolumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
lenvatinib mesylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
nevanimibe hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
niraparib - Drug Profile
Product Description
Mechanism Of Action
History of Events
omburtamab - Drug Profile
Product Description
Mechanism Of Action
History of Events
OR-449 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
relacorilant - Drug Profile
Product Description
Mechanism Of Action
History of Events
SVV-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones
Featured News & Press Releases
Jun 14, 2022: Orphagen Pharmaceuticals presents data on downstream targets of SF-1 Antagonist OR-449 at ENDO 2022
Jun 04, 2018: Infinity Reports IPI-549 Clinical and Translational Data from Ongoing Phase 1/1b Study at American Society of Clinical Oncology Annual Meeting
Jan 08, 2018: Infinity Provides Update on IPI-549 Phase I/Ib Study, 2018 Goals and Financial Guidance
Nov 10, 2017: Infinity Pharmaceuticals Reports IPI-549 Clinical and Translational Data from Completed Monotherapy Dose-Escalation Component of Phase 1/1b Clinical Study in Patients with Advanced Solid Tumors at SITC Annual Meeting
Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing's Syndrome
Mar 18, 2016: Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016
Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2015
Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers
Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Bristol-Myers Squibb Co, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Corcept Therapeutics Inc, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Eisai Co Ltd, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Enterome Bioscience SA, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Exelixis Inc, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Fusion Pharmaceuticals Inc, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by GSK plc, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Infinity Pharmaceuticals Inc, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck & Co Inc, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck KGaA, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals Inc, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Pharma Mar SA, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Sanofi, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Seneca Therapeutics Inc, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Tempest Therapeutics Inc, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Y-mAbs Therapeutics Inc, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, 2022
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Adrenocortical Carcinoma (Adrenal Cortex Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW